Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate.

Authors

Bishnuhari Paudyal, Department of Radiology, Thomas Jefferson University; Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, JapanFollow
Pramila Paudyal, Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan
Dilip Shah, Center of Translational Medicine and Division of Pulmonary and Critical Care Medicine, Thomas Jefferson UniversityFollow
Hideyuki Tominaga, Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan
Yoshito Tsushima, Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan
Keigo Endo, Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan; Kyoto College of Medical Science, Nantan, Kyoto 6220041, Japan

Document Type

Article

Publication Date

4-29-2014

Comments

This article has been peer reviewed. It was published in: Journal of Biomedical Science.

Volume 21, Issue 1, 29 April 2014, Article number 35.

The published version is available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012715/

Copyright © 2014 Paudyal et al.

Abstract

BACKGROUND: The aim of this study was to develop the near infrared fluorescence (NIRF)-based imaging agent for the visualization of vascular endothelial growth factor (VEGF) in colon cancer. AlexaFluor 750 conjugating with bevacizumab, and injected intravenously into nude mice bearing VEGF over-expressing HT29 human colorectal cancer. Optical imaging was performed at 15 min, 24 h and 48 h post injection. Immunofluorescences staining of the tumor sections were performed. HT29 colorectal cancer xenografts were clearly visualized with bevacizumab-AlexaFluor 750.

RESULTS: Ex vivo analysis showed 2.1 ± 0.4%, 37.6 ± 6.3% and 38.5 ± 6.2% injected dose/g accumulated in the tumors at 15 min, 24 h and 48 h respectively. Tumor uptake was significantly decreased in pretreated with excess of bevacizumab (p = 0.002). Immunofluorescence analysis showed strong staining of anti-CD 31 antibody around the blood vessels. Anti-VEGF-A and bevacizumab showed heterogeneous expression throughout the tumor.

CONCLUSIONS: Current study successfully detected the VEGF expression in HT29 colorectal cancer xenografts, signifying as a potential agent for non-invasive imaging of VEGF expression, which may be applied in clinical practice.

Recommended Citation

Paudyal, Bishnuhari; Paudyal, Pramila; Shah, Dilip; Tominaga, Hideyuki; Tsushima, Yoshito; and Endo, Keigo, "Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate." (2014). Department of Radiology Faculty Papers. Paper 35.
https://jdc.jefferson.edu/radiologyfp/35

PubMed ID

24780003